SCHEMBL381832

SCHEMBL381832

CCN(C(C)=O)c1ccc(Br)cc1C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 4/20 0.47
RARB P10826 4/20 0.47
RARG P13631 4/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.44
RBP4 P02753 1/20 0.38
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
LMNA P02545 4/20 0.36
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
USP2 O75604 1/20 0.34
ALPL P05186 1/20 0.34
ALOX15 P16050 1/20 0.34
HDAC8 Q9BY41 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
RIPK1 Q13546 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1856405 0.82 RARA (0.52) RARARARBRARGHSP90AA1HSP90AB1
SCHEMBL1860565 0.80 RARA (0.48) RARARARBRARGHSP90AA1HSP90AB1
SCHEMBL381965 0.77 ALDH1A1 (0.41) RARARARBRARGPTGDR2RBP4
SCHEMBL2098379 0.71 PTGDR2 (0.40) PTGDR2RBP4LMNAALDH1A1USP2
SCHEMBL1863424 0.70 RARA (0.54) RARARARBRARGLMNAMEN1
SCHEMBL2098886 0.70 PTGDR2 (0.35) RARARARBRARGPTGDR2RBP4
SCHEMBL898260 0.70 PTGDR2 (0.54) PTGDR2RBP4MEN1KMT2A
SCHEMBL8342856 0.70 ALDH1A1 (0.47) LMNAALDH1A1RECQLL3MBTL1USP2
SCHEMBL2083223 0.68 MTNR1A (0.48) LMNAALDH1A1L3MBTL1HDAC8SMN1; SMN2
SCHEMBL28048251 0.67 ESR1 (0.45) LMNAALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470871-B2 Ligands that modulate RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-06-25 US disclosed
US-20120258996-A1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-10-11 US disclosed
US-8227507-B2 Ligands that modulate RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-07-24 US disclosed
EP-1831149-B1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2012-01-25 EP disclosed
EP-1680395-B1 NOVEL LIGAND ACTIVATING RAR RECEPTORS USED IN HUMAN MEDICINE AND COSMETICS GALDERMA RES & DEV (FR) 2011-05-25 EP disclosed
US-20100292296-A1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-11-18 US disclosed
US-7807708-B2 Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-10-05 US disclosed
US-7439396-B2 Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-10-21 US disclosed
US-20080015246-A1 Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-17 US disclosed
EP-1831149-A1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-12 EP disclosed
US-20070004726-A1 Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2007-01-04 US disclosed
EP-1680395-A2 NOVEL LIGAND ACTIVATING RECEPTORS RARS USED FOR HUMAN MEDICINE AND COSMETICS Galderma Research & Development, S.N.C. (FR) 2006-07-19 EP disclosed
WO-2006066978-A1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-06-29 WO disclosed
WO-2005037772-A2 NOVEL LIGAND ACTIVATING RECEPTORS RARS USED FOR HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015246-A1 Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof RARB, RARA, RARG RARA 2/4885RARB 1/4885RARG 3/4885
US-20120258996-A1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS RARB, RARA, RARG RARA 2/4885RARB 1/4885RARG 3/4885
US-20070004726-A1 Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors RARA, RARG, RARB RARA 1/4885RARB 3/4885RARG 2/4885
US-20100292296-A1 NOVEL LIGANDS THAT MODULATE RAR RECEPTORS RARB, RARA, RARG RARA 2/4885RARB 1/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.